ARUP Will Showcase Advances in Hematopathology at the 66th ASH Annual Meeting and Exposition

ARUP medical directors and scientists have made major contributions to the advancement of hematopathology, and their research will be highlighted at the upcoming 66th American Society of Hematopathology (ASH) Annual Meeting and Exposition. The conference, which will be held in San Diego, California, December 7–10, 2024, provides an opportunity for those in the hematology field to share research and collaborate.

Tracy I. George, MD, ARUP chief scientific officer and president of the Innovation Business Unit, and Jay Patel, MD, MBA, vice president of PharmaDx and Clinical Trials at ARUP, have contributed to recent developments in the treatment of advanced systemic mastocytosis. They will present an update on Part 1 of the Apex trial, which focused on dose optimization.

The poster session, “Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM),” will be held on Sunday, December 8, 2024, at 5:30 p.m.

Robert Ohgami, MD, PhD, FCAP, vice president of the ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine™, contributed to research on Castleman disease. The presentation of this research is entitled, “Burden of Idiopathic Multicentric Castleman Disease (iMCD) in the US: A Population-Level Real World Analysis Using a Health-Claims Dataset,” and will be given on Monday, December 9, 2024, at 10:30 a.m.

The complete schedule of presentations and posters by ARUP scientists and medical directors is available below.

ASH attendees will have an opportunity to speak with ARUP’s hematopathologists about their research and other developments in laboratory medicine by visiting booth #2455 in the exhibit hall. There will also be information available on ARUP’s latest innovations in laboratory medicine and robust test menu for hematologic disease.

One key advancement includes ARUP’s Myeloid Malignancies Mutation and Copy Number Variation Panel by Next Generation Sequencing (3016621). The panel, developed by ARUP, is the first of its kind to use next generation sequencing (NGS) to identify small, intermediate, and large structural abnormalities in a single assay, including copy number variants (CNVs) and copy number-neutral loss of heterozygosity (CN-LOH). The test provides essential information for the diagnosis, subclassification, and risk stratification of hematologic malignancies, based on updated guidelines from the World Health Organization (WHO) and the International Consensus Classification (ICC).

ARUP, which is home to one of the nation’s largest groups of hematopathology experts, also offers an ongoing expert webinar series on timely issues related to hematopathology. Access the latest webinar in the series here.

To learn more about ARUP’s robust test menu for blood and bone marrow disorders, visit https://www.aruplab.com/hematopathology.

Kellie Carrigan, kellie.carrigan@aruplab.com

Schedule of Presentations and Posters

Presentations

Sunday, December 8, 2024, Session 634
Grand Hall D (Manchester Grand Hyatt San Diego)

5:30 PM

• 659. Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)
  Daniel J. DeAngelo, MD, PhD; Jason Gotlib, MD, MS; Vinod Pullarkat, MD, et al
  ARUP Contributors: Tracy I. George, MD; Jay Patel, MD, MBA

Monday, December 9, 2024, Session 905
Room 6B (San Diego Convention Center)

11:30 AM

• 797. Burden of Idiopathic Multicentric Castleman Disease (iMCD) in the US: A Population-Level Real World Analysis Using a Health-Claims Dataset
  Ariela Noy, MD; Robert Ohgami, MD, PhD; Nikhil C. Munshi, MD, et al
  ARUP Contributor: Robert Ohgami, MD, PhD, FCAP

Posters

Saturday, December 7, 2024, 5:30–7:30 PM 
Halls G-H (San Diego Convention Center)

Session 330

• 1227. Clonal Persistence of Anti-PF4 Antibodies in VITT Represents an MGTS-like State
  Adam Kanack, PhD; Guillaume Roberge, MD; Emily Mauch, BS, et al
  ARUP Contributor: Kristi J. Smock, MD

Session 503

• 1296. Clonal Hematopoiesis and Germline Predisposition in High-Risk Leukemia Pedigrees
  Afaf Osman, MD; Julie Feusier, PhD; Brian Avery, PhD, et al
  ARUP Contributors: Julie Feusier, PhD; Adam Clayton; Philippe Szankasi, PhD; Jay Patel, MD, MBA

Sunday, December 8, 2024, 6:00–8:00 PM
Halls G-H (San Diego Convention Center)

Session 509

• 2704. Prospective Genomic Study for Optimizing Clonal Hematopoiesis Surveillance in Bone Marrow Failure Syndromes and Related Cytopenia
  Enrico Attardi, MD; Nathan Gray, PA-C; Sara Lewis, MS, CGC, et al
  ARUP Contributors: Peng Li, MD, PhD; Erica F. Andersen, PhD, FACMG; Jian Zhao, PhD; Lucilla Pizzo, PhD; Bo Hong, MD, FACMG

Session 621

• 2976. HIV-Associated Diffuse Large B-Cell Lymphoma Shows Different Genomic Patterns between EBV-Positive and EBV-Negative Tumors
  Joo Y. Song, MD; Jibin Zhang, PhD; David W. Scott, MBChB, PhD, et al
  ARUP Contributor: Madhu P. Menon, MD, PhD

Session 634

• 3164. Ultra-Sensitive KIT Testing Uncovers Previously Undetected KIT Mutations in Patients with Indolent Systemic Mastocytosis: Results from the Pioneer Trial
  Deepti H. Radia, MD; Tsewang Tashi, MD, PhD; Ivan Alvarez-Twose, MD, PhD, et al
  ARUP Contributor: Tracy I. George, MD

Session 702

• 3409. Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL
  Devang Thakkar; Brian T. Hill, MD, PhD; Rachel Kositsky, et al
  ARUP Contributor: Robert Ohgami, MD, PhD, FCAP

Monday, December 9, 2024, 6:00–8:00 PM
Halls G-H (San Diego Convention Center)

Session 634

• 4544. Disease-Modifying Effects of Avapritinib in Patients with Advanced Systemic Mastocytosis: Improvements in Bone Density
  Johannes Luebke, MD; Tracy I. George, MD; Daniel J. DeAngelo, MD, et al
  ARUP Contributor: Tracy I. George, MD
• 4556. Updated Efficacy and Safety Results of Patients Receiving Selected 100mg Bezuclastinib Dose and Participating in the Open-Label Extension of Summit: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis
  Lindsay A.M. Rein, MD; Daniel J. DeAngelo, MD, PhD; Brian Modena, MD, et al
  ARUP Contributors: Tracy I. George, MD; Jay Patel, MD, MBA
• 4569.1. Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis
  Isaac Goncalves, MBBS, PhD; Stephen Fuller; Jason Gotlib, MD, MS, et al
  ARUP Contributors: Tracy I. George, MD; Jay Patel, MD, MBA